Skip to content

Study · Randomized controlled trial · n = 162 · 2011

4 results

Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial.

Manno C, Bonifati C, Torres DD, Campobasso N, Schena FP

American journal of kidney diseases : the official journal of the National Kidney Foundation26 Feb 2011Cited by 76 (Europe PMC)

PMID21354681 (opens in a new tab)DOI10.1053/j.ajkd.2010.12.019 (opens in a new tab)PepBankPUB-21354681
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In kidney-biopsy patients, desmopressin reduced bleeding versus placebo (11 of 80 versus 25 of 82, relative risk 0.45, P = 0.01).

    In plain wordsIn kidney-biopsy patients, desmopressin reduced bleeding compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreasePostbiopsy bleeding
    Study

    n = 162

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bleeding · Kidney and urinary
    Studied dose
    0.3 μg/kg · subcutaneousAs given in this study (human).

    Measurements

    Postbiopsy bleeding, patients
    11 patients
    desmopressin group, of 80
    Postbiopsy bleeding, patients
    25 patients
    placebo group, of 82
    Postbiopsy bleeding incidence
    13.7%
    desmopressin group
    Postbiopsy bleeding incidence
    30.5%
    placebo group
    Relative risk of postbiopsy bleeding
    0.45
    desmopressin vs placebo
    95% CI of relative risk
    0.24 to 0.85
    desmopressin vs placebo
    P value
    0.01
    bleeding, desmopressin vs placebo

    Source sentences

    Summary
    Desmopressin compared with placebo significantly decreased the risk of postbiopsy bleeding (11 of 80 [13.7%] vs 25 of 82 [30.5%]; relative risk, 0.45; 95% CI, 0.24-0.85; P = 0.01)
    3 context sentences
    Summary · context
    Double-blind randomized controlled clinical trial.
    Summary · context
    We examined prebiopsy subcutaneous administration of desmopressin acetate, 0.3 μg/kg, compared with placebo.
    Summary · context
    162 adult patients (88 men and 74 women) were enrolled; 80 were allocated to desmopressin treatment, and 82, to the placebo group.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In kidney-biopsy patients, desmopressin shortened mean hospital stay versus placebo (4.9 ± 1.1 versus 5.9 ± 1.7 days, P = 0.004).

    In plain wordsIn kidney-biopsy patients, desmopressin shortened hospital stay compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseHospital stay
    Study

    n = 162

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    0.3 μg/kg · subcutaneousAs given in this study (human).

    Measurements

    Mean hospital stay
    4.9 days
    desmopressin group
    SD of hospital stay
    1.1 days
    desmopressin group
    Mean hospital stay
    5.9 days
    placebo group
    SD of hospital stay
    1.7 days
    placebo group
    P value
    0.004
    hospital stay, desmopressin vs placebo

    Source sentences

    Summary
    and mean hospital stay (4.9 ± 1.1 vs 5.9 ± 1.7 days; P = 0.004)
    3 context sentences
    Summary · context
    Double-blind randomized controlled clinical trial.
    Summary · context
    We examined prebiopsy subcutaneous administration of desmopressin acetate, 0.3 μg/kg, compared with placebo.
    Summary · context
    162 adult patients (88 men and 74 women) were enrolled; 80 were allocated to desmopressin treatment, and 82, to the placebo group.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In kidney-biopsy patients with bleeding, desmopressin reduced median hematoma size versus placebo (208 versus 380 mm(2), P = 0.006).

    In plain wordsIn kidney-biopsy patients with bleeding, desmopressin reduced blood collection size compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseHematoma size
    Study

    n = 36

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Bleeding · Kidney and urinary
    Studied dose
    0.3 μg/kg · subcutaneousAs given in this study (human).

    Measurements

    Median hematoma size
    208 mm(2)
    desmopressin group, patients with bleeding
    Interquartile range of hematoma size
    120 to 300 mm(2)
    desmopressin group, 25th-75th percentile
    Median hematoma size
    380 mm(2)
    placebo group, patients with bleeding
    Interquartile range of hematoma size
    270 to 570 mm(2)
    placebo group, 25th-75th percentile
    P value
    0.006
    hematoma size, desmopressin vs placebo

    Source sentences

    Summary
    hematoma size (median, 208 [25th-75th percentile, 120-300] vs 380 [25th-75th percentile, 270-570] mm(2); P = 0.006] in the 36 patients who experienced bleeding
    3 context sentences
    Summary · context
    Double-blind randomized controlled clinical trial.
    Summary · context
    We examined prebiopsy subcutaneous administration of desmopressin acetate, 0.3 μg/kg, compared with placebo.
    Summary · context
    162 adult patients (88 men and 74 women) were enrolled; 80 were allocated to desmopressin treatment, and 82, to the placebo group.
  4. 04HumanNon-randomized trialEfficacy outcome

    In kidney-biopsy patients, postbiopsy hemoglobin was not significantly affected in either desmopressin or placebo groups.

    In plain wordsIn kidney-biopsy patients, blood hemoglobin did not change significantly in either the desmopressin or placebo group.

    Peptide
    Desmopressin
    Outcome
    No significant changePostbiopsy hemoglobin
    Study

    n = 162

    Analysis
    Secondary
    Outcome group
    Bleeding · Kidney and urinary
    Studied dose
    0.3 μg/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    postbiopsy hemoglobin levels were not affected significantly in either group.
    3 context sentences
    Summary · context
    Double-blind randomized controlled clinical trial.
    Summary · context
    We examined prebiopsy subcutaneous administration of desmopressin acetate, 0.3 μg/kg, compared with placebo.
    Summary · context
    162 adult patients (88 men and 74 women) were enrolled; 80 were allocated to desmopressin treatment, and 82, to the placebo group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Enrolling by invitationPhase 4NCT06622187

Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies

Hospital de Clinicas de Porto Alegren = 9614 Aug 2024 to est. 14 Jun 2026

Bleeding · Transplant, Kidney · Desmopressin · Kidney Biopsy

Trial pageClinicalTrials.govUpdated 11 Sept 2025
CompletedPhase 4Results postedNCT00748072

1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy

University of Barin = 162Aug 2008 to Dec 2009

Kidney Failure

Trial pageClinicalTrials.govUpdated 13 Jan 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.